Signature phaco machine offers good stability

Article

Anterior chamber fluctuations during phacoemulsification can cause an increase in retinal thickness and alterations of the blood aqueous barrier. In order to avoid these complications, it is better to use a machine that offers good anterior chamber stability.

Anterior chamber fluctuations during phacoemulsification can cause an increase in retinal thickness and alterations of the blood aqueous barrier. In order to avoid these complications, it is better to use a machine that offers good anterior chamber stability, according to Alessandro Franchini and colleagues from the University of Florence, Italy.

The researchers used a micro silicon sensor interfaced with a control unit, inserted in the anterior chamber during phacoemulsification to continuously monitor the anterior chamber tension in three groups of 20 patients being operated on with three different phacoemulsifiers: Sovereign WhiteStar (AMO), Signature (AMO) and Legacy Everest (Alcon).

The average anterior chamber variation during phacoemulsification was 7.2 mmHg using the Signature, 15.5 mmHg with the WhiteStar and 16.3 mmHg using the Legacy (Signature vs WhiteStar: p<0.05; Signature vs Legacy: p<0.001; WhiteStar vs Legacy: p=0.132).

Anterior fluctuations can cause complications so it is best to use a machine that can guarantee anterior chamber stability. With this in mind the authors recommend using AMOs Signature system to control fluidics thus reducing fluctuations.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.